Trial reportScientific reports2026
Optimizing butorphanol-dexmedetomidine dosing for managing catheter-related bladder discomfort post-anesthesia: a randomized trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Catheter-related bladder discomfort (CRBD) during anesthesia recovery increases postoperative risks and healthcare burden. This single-center randomised controlled trial evaluated the efficacy and safety of three regimens: DSF (dexmedetomidine 0.2 µg/kg plus sufentanil 0.1 µg/kg), DLB (dexmedetomidine 0.2 µg/kg plus butorphanol 10 µg/kg), and DHB (dexmedetomidine 0.2 µg/kg plus butorphanol 20 µg/kg), for managing moderate-to-severe CRBD in 102 adult patients. Primary outcomes measured CRBD severity scores and response rates (score of ≤ 1), while secondary outcomes assessed haemodynamic stability, respiratory depression, analgesia, sedation, and other parameters. Results demonstrated significant CRBD reduction across all groups post-intervention (P < 0.001). At 15 min, the dexmedetomidine-butorphanol groups achieved markedly higher response rates (DLB: 83.3%; DHB: 65.6%) than the dexmedetomidine-sufentanil group (DSF: 23.5%, P < 0.0001). The DLB group exhibited superior haemodynamic stability, avoiding heart rate fluctuations observed in DSF and DHB, along with a lower respiratory depression (13.9% vs. 41.2% in DSF, P = 0.0103). Additionally, DLB provided enhanced postoperative analgesia (lower NRS scores vs. DSF, P < 0.05) and reduced oversedation rates (52.8% at 5 min vs. 82.4% in DSF and 81.3% in DHB, P < 0.05). The findings suggest that combining 0.2 µg/kg dexmedetomidine with 10 µg/kg butorphanol offers rapid, effective CRBD relief alongside improved postoperative analgesia, while minimising sedation and respiratory risks. This regimen presents a safer strategy for CRBD during anaesthesia recovery. Trial registration: Chinese Clinical Trial Registry, identifier: ChiCTR2400091174, Date: 22/10/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.